3/21/2019 · ENCORE-NF is one of three randomized, double-blind, placebo-controlled Phase 2b clinical trials conducted by Conatus in collaboration with Novartis, the EmricasaN, a Caspase inhibitOR, for …
3/21/2019 · ENCORE-NF is one of three randomized, double-blind, placebo-controlled Phase 2b clinical trials conducted by Conatus in collaboration with Novartis, the EmricasaN, a Caspase inhibitOR, for Evaluation (ENCORE) trials, designed to evaluate emricasan in.
1/12/2016 · The ENCORE-NF clinical trial is the first of multiple parallel EmricasaN, a Caspase inhibitOR, for Evaluation (ENCORE) Phase 2b clinical trials designed to evaluate multiple doses of emricasan over various treatment durations in chronic liver disease of different etiologies and disease stages.
3/21/2019 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support, Conatus Pharmaceuticals Inc. announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s primary endpoint was a ?1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72.
encore-nf. Technically Swinging CNAT. February 21, 2019 by Kevin Douglass Leave a Comment. Swing Thesis This swing-trade for Conatus Pharmaceuticals, (Nasdaq: CNAT) is based on Technical Analysis (which aligns with some key dates) and a fundamental component. With regards to technical.
3/21/2019 · About ENCORE-NF The randomized, double-blind ENCORE-NF Phase 2b clinical trial, initiated in the first quarter of 2016, enrolled and treated 318.
8/15/2017 · The ENCORE-NF clinical trial is being conducted at approximately 100 U.S. and EU clinical sites. Patients were randomized 1:1:1 to receive 5 mg of emricasan, 50 mg of emricasan, or placebo twice daily for 72 weeks. The primary endpoint is a biopsy-based improvement in fibrosis by at least one stage vs. placebo using NASH CRN without worsening …
